| Name | GSK2200150A |
| Description | GSK2200150A is an anti-tuberculosis (TB) agent identified by high-throughput screening (HTS) campaign. |
| Cell Research | GSK2200150A is tested for activity at either single concentration (100 μM) or serially diluted in 10 μL of purified H2O in triplicate in 96 well microtiter plates. M. tuberculosis H37Rv is grown in complete Middlebrook 7H9 media containing albumin, dextrose and catalase (ADC), 20% Tween 80 and 50% glycerol. A bacterial suspension (90 μL) at OD600 nm of 0.001 is added to the wells and incubated for 7 days. Resazurin (10 μL; 0.05%(w/v)) is then added, incubated for 24 h at 37°C, and fluorescence measured at 590 nm using a FLUOstar Omega microplate reader. After subtraction of background fluorescence from all wells, the percentage mycobacterial survival is determined by comparing the fluorescence of wells containing compounds compared to control wells not treated with compound[1]. |
| In vitro | GSK2200150A, a novel agent with a spirocycle core, exhibits strong antimycobacterial properties against the virulent Mycobacterium tuberculosis strain (H37Rv), demonstrating a minimal inhibitory concentration (MIC) of 0.38 μM [1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 45 mg/mL (125.88 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.59 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | GSK-2200150A | GSK2200150A | Bacterial |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Bioactive Compound Library | NO PAINS Compound Library | Anti-Bacterial Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library |
United States
